Royalty Pharma beats Q3 2026 expectations and raises guidance
FROM THE WIRE · FINANCE.YAHOO.COM
Royalty Pharma reported third quarter 2026 results with portfolio receipts of US$890 million and earnings of US$1.21 per share, both ahead of analyst expectations, alongside reported GAAP revenue of US$690.1 million and net income of US$144.68 million. The business raised full…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishEarnings and receipts above expectations, with guidance raised for a third straight quarter, support the stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Royalty Pharma reported earnings of $1.21 per share, ahead of expectations.
- 02Portfolio receipts for the third quarter were $890 million.
- 03The company raised its full-year 2026 portfolio receipts guidance for the third consecutive quarter.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets